These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 7602100)

  • 21. The role of CD4+ T cells in immunity to malaria sporozoites.
    Weiss WR; Sedegah M; Berzofsky JA; Hoffman SL
    J Immunol; 1993 Sep; 151(5):2690-8. PubMed ID: 8103069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of protective polyclonal antibodies by immunization with a Plasmodium yoelii circumsporozoite protein multiple antigen peptide vaccine.
    Wang R; Charoenvit Y; Corradin G; Porrozzi R; Hunter RL; Glenn G; Alving CR; Church P; Hoffman SL
    J Immunol; 1995 Mar; 154(6):2784-93. PubMed ID: 7876549
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunization with a recombinant C-terminal fragment of Plasmodium yoelii merozoite surface protein 1 protects mice against homologous but not heterologous P. yoelii sporozoite challenge.
    Rénia L; Ling IT; Marussig M; Miltgen F; Holder AA; Mazier D
    Infect Immun; 1997 Nov; 65(11):4419-23. PubMed ID: 9353014
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant Mycobacterium bovis bacillus Calmette-Guérin secreting merozoite surface protein 1 (MSP1) induces protection against rodent malaria parasite infection depending on MSP1-stimulated interferon gamma and parasite-specific antibodies.
    Matsumoto S; Yukitake H; Kanbara H; Yamada T
    J Exp Med; 1998 Sep; 188(5):845-54. PubMed ID: 9730886
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of protection induced by immunization with recombinant proteins from different regions of merozoite surface protein 1 of Plasmodium yoelii.
    Tian JH; Kumar S; Kaslow DC; Miller LH
    Infect Immun; 1997 Aug; 65(8):3032-6. PubMed ID: 9234750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Passive immunization with antibodies against three distinct epitopes on Plasmodium yoelii merozoite surface protein 1 suppresses parasitemia.
    Spencer Valero LM; Ogun SA; Fleck SL; Ling IT; Scott-Finnigan TJ; Blackman MJ; Holder AA
    Infect Immun; 1998 Aug; 66(8):3925-30. PubMed ID: 9673281
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice.
    Devi YS; Mukherjee P; Yazdani SS; Shakri AR; Mazumdar S; Pandey S; Chitnis CE; Chauhan VS
    Vaccine; 2007 Jul; 25(28):5166-74. PubMed ID: 17544179
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunity to erythrocytic stages of malarial parasites.
    Long CA; Daly TM; Kima P; Srivastava I
    Am J Trop Med Hyg; 1994; 50(4 Suppl):27-32. PubMed ID: 7909653
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subpatent infection with nucleoside transporter 1-deficient Plasmodium blood stage parasites confers sterile protection against lethal malaria in mice.
    Aly AS; Downie MJ; Mamoun CB; Kappe SH
    Cell Microbiol; 2010 Jul; 12(7):930-8. PubMed ID: 20088947
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interdependence of CD4+ T cells and malarial spleen in immunity to Plasmodium vinckei vinckei. Relevance to vaccine development.
    Kumar S; Good MF; Dontfraid F; Vinetz JM; Miller LH
    J Immunol; 1989 Sep; 143(6):2017-23. PubMed ID: 2570802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trials for the co-expression of the merozoite surface protein-1 and circumsporozoite protein genes of Plasmodium vivax.
    Lee C; Chung KW; Kim TS; Choi KM; Choi YK; Chung NJ; Rhie HG; Lee HS; Lee SJ; Lee HW
    Exp Parasitol; 2011 Nov; 129(3):227-33. PubMed ID: 21907198
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The combined epidermal growth factor-like modules of Plasmodium yoelii Merozoite Surface Protein-1 are required for a protective immune response to the parasite.
    Ling IT; Ogun SA; Holder AA
    Parasite Immunol; 1995 Aug; 17(8):425-33. PubMed ID: 7501423
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced protection against malaria by a chimeric merozoite surface protein vaccine.
    Shi Q; Lynch MM; Romero M; Burns JM
    Infect Immun; 2007 Mar; 75(3):1349-58. PubMed ID: 17158895
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Passive immunization against murine malaria with an IgG3 monoclonal antibody.
    Majarian WR; Daly TM; Weidanz WP; Long CA
    J Immunol; 1984 Jun; 132(6):3131-7. PubMed ID: 6725950
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intranasal immunization with yeast-expressed 19 kD carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (yMSP119) induces protective immunity to blood stage malaria infection in mice.
    Hirunpetcharat C; Stanisic D; Liu XQ; Vadolas J; Strugnell RA; Lee R; Miller LH; Kaslow DC; Good MF
    Parasite Immunol; 1998 Sep; 20(9):413-20. PubMed ID: 9767608
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Production, characterisation and immunogenicity of a plant-made Plasmodium antigen--the 19 kDa C-terminal fragment of Plasmodium yoelii merozoite surface protein 1.
    Ma C; Wang L; Webster DE; Campbell AE; Coppel RL
    Appl Microbiol Biotechnol; 2012 Apr; 94(1):151-61. PubMed ID: 22170105
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CpG oligodeoxynucleotide enhances immunity against blood-stage malaria infection in mice parenterally immunized with a yeast-expressed 19 kDa carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (MSP1(19)) formulated in oil-based Montanides.
    Hirunpetcharat C; Wipasa J; Sakkhachornphop S; Nitkumhan T; Zheng YZ; Pichyangkul S; Krieg AM; Walsh DS; Heppner DG; Good MF
    Vaccine; 2003 Jun; 21(21-22):2923-32. PubMed ID: 12798636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Merozoite surface protein-1 of Plasmodium yoelii fused via an oligosaccharide moiety of cholera toxin B subunit glycoprotein expressed in yeast induced protective immunity against lethal malaria infection in mice.
    Miyata T; Harakuni T; Taira T; Matsuzaki G; Arakawa T
    Vaccine; 2012 Jan; 30(5):948-58. PubMed ID: 22119928
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasmodium yoelii yoelii 17XL MSP-1: fine-specificity mapping of a discontinuous, disulfide-dependent epitope recognized by a protective monoclonal antibody using expression PCR (E-PCR).
    Farley PJ; Long CA
    Exp Parasitol; 1995 Mar; 80(2):328-32. PubMed ID: 7534725
    [No Abstract]   [Full Text] [Related]  

  • 40. Effect of nanoparticle coating on the immunogenicity of plasmid DNA vaccine encoding P. yoelii MSP-1 C-terminal.
    Shuaibu MN; Cherif MS; Kurosaki T; Helegbe GK; Kikuchi M; Yanagi T; Sasaki H; Hirayama K
    Vaccine; 2011 Apr; 29(17):3239-47. PubMed ID: 21354479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.